Osteoporosis: a clinical and pharmacological update

Vidal, Maritza; Thibodaux, Ross J.; Neira, Luis Fernando Vidal; Messina, Osvaldo Daniel

doi:10.1007/s10067-018-4370-1

Cited by 49 publications

(36 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, the aging of the world's population is increasing and the incidence of OP is increasing, bringing great troubles to society and individuals. 39 Finding effective biomarkers for early diagnosis of OP and developing effective therapeutic drugs with denite curative effect, safety and stability are the urgent problems for researchers at present. As the pathogenesis of OP is still unclear and no effective early diagnosis basis has been determined, therapeutic drugs with denite curative effect and high cure rate have not been developed.…”

Section: Discussionmentioning

confidence: 99%

Untargeted metabolomics using liquid chromatography coupled with mass spectrometry for rapid discovery of metabolite biomarkers to reveal therapeutic effects ofPsoralea corylifoliaseeds against osteoporosis

Zhao

Zhang

et al. 2019

RSC Adv.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Untargeted metabolomics using liquid chromatography coupled with mass spectrometry for rapid discovery of metabolite biomarkers to reveal therapeutic effects ofPsoralea corylifoliaseeds against osteoporosis

Zhao

Zhang

et al. 2019

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…For example, studies have found non-adherence to bisphosphonates in men ranging from one-third to two-thirds, with subsequent increased fracture risk (74). Therefore, therapeutic success of osteoporosis treatment in men can be measured by different methods, such as absence of fractures, increment or maintaining BMD, compliance with therapy (75). Following precise diagnosis, adequate management of male osteoporosis requires a careful selection of patients candidates to receive specific treatment, life style interventions, treatment of underlying conditions, and decision on which drug to use.…”

Section: General Considerationsmentioning

confidence: 99%

“…Nevertheless, TRT alone is not recommended and should be associated with antiresorptive drugs when fracture risk is high (12). Actually, the effect of TRT alone on bone health in hypogonadal men is still not well defined (75), and no studies with fractures as primary end point have been performed. Indeed, TRT can improve BMD, particularly at the vertebral level and when testosterone levels are very low (12,83).…”

Section: Supplement and Replacement Therapymentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Male osteoporosis: diagnosis and management - should the treatment and the target be the same as for female osteoporosis?

Porcelli

Maffezzoni

Pezzaioli

et al. 2020

European Journal of Endocrinology

View full text Add to dashboard Cite

Male osteoporosis has been neglected for too long time and there is need for a change. This condition is clearly under-estimated, under-diagnosed and under-treated. The diagnosis is often made late in the natural history of the pathology or even after a fracture event. Guidelines on screening politics do not agree whether and when men should be considered, and clinical trials are far less performed in men with respect to women. Actually, most of our knowledge on male osteoporosis, especially regarding treatment, is extrapolate from the female counterpart. Male osteoporosis is frequently secondary to other conditions and often associated with comorbidities. Therefore, identification of specific causes of male osteoporosis is essential to drive a correct and personalized treatment. Moreover, men have more osteoporosis-related complications and higher mortality rate associated with fractures. Furthermore, not only fewer men receive a correct and timely diagnosis, but also fewer men receive adequate treatment, and adherence to therapy is far less in men than in women. Of note, very few studies assessed the effect of anti-osteoporotic treatments in men and most of them considered only bone density as primary endpoint. This review focuses on the areas that are still nebulous in male osteoporosis field, from identification of subjects who need to be evaluated for osteoporosis and screening programs dealing with primary prevention, to diagnostic procedures for good estimates of bone quantity and quality and precise calculation of fracture risk, and personalized treatment that take into account the pathophysiology of osteoporosis.

show abstract

“…Osteoporosis is one of the emerging health problems of aging societies in developed countries. It is estimated that 200 million people worldwide suffer from osteoporosis and the incidence is still growing . Currently, one out of three women and one out of five men aged over 50 years will experience an osteoporotic fracture during their life .…”

Section: Comorbidities Influencing Fracture Healingmentioning

confidence: 99%

Review of Animal Models of Comorbidities in Fracture‐Healing Research

Haffner‐Luntzer¹,

Hankenson

Ignatius³

et al. 2019

Journal Orthopaedic Research

View full text Add to dashboard Cite

There is clinical evidence that patient-specific comorbidities like osteoporosis, concomitant tissue injury, and ischemia may strongly interfere with bone regeneration. However, underlying mechanisms are still unclear. To study these mechanisms in detail, appropriate animal models are needed. For decades, bone healing has been studied in large animals, including dogs, rabbits, pigs, or sheep. However, large animal models display a limited ability to study molecular pathways and cellular functions. Therefore in recent years, mice and rats have become increasingly popular as a model organism for fracture healing research due to the availability of molecular analysis tools and transgenic models. Both large and small animals can be used to study comorbidities and risk factors, modelling the human clinical situation. However, attention has to be paid when choosing an appropriate model due to species differences between large animals, rodents, and humans. This review focuses on large and small animal models for the common comorbidities ischemic injury/reduced vascularization, osteoporosis, and polytrauma, and critically discusses the translational and molecular aspects of these models. Here, we review material which was presented at the workshop "Animal

show abstract

Osteoporosis: a clinical and pharmacological update

Cited by 49 publications

References 92 publications

Untargeted metabolomics using liquid chromatography coupled with mass spectrometry for rapid discovery of metabolite biomarkers to reveal therapeutic effects ofPsoralea corylifoliaseeds against osteoporosis

Untargeted metabolomics using liquid chromatography coupled with mass spectrometry for rapid discovery of metabolite biomarkers to reveal therapeutic effects ofPsoralea corylifoliaseeds against osteoporosis

MANAGEMENT OF ENDOCRINE DISEASE: Male osteoporosis: diagnosis and management - should the treatment and the target be the same as for female osteoporosis?

Review of Animal Models of Comorbidities in Fracture‐Healing Research

Contact Info

Product

Resources

About